FDA Approved (Spravato 2019)
Ketamine Therapy
FDA-approved for treatment-resistant depression via the nasal spray Spravato (esketamine). Ketamine clinics are available nationwide offering both IV infusions and the FDA-approved formulation.
50Clinical Trials
10Companies
0Legal States
FDA StatusFDA Approved (Spravato 2019)
Legal PathwayAlready legal via prescription
Also Known AsSpravato, esketamine, ketamine infusion
Clinical Trials
Phase 110
Phase 211
Phase 34
Active, Not Recruiting·Phase 2·ketamine
A Clinical Trial of Add-on Oral Slow-release Ketamine Treatment in Major Depression
Daniel Lindqvist
Major Depressive Disorder (MDD)
Active, Not Recruiting·Early Phase 1·ketamine
Evaluation of Ketamine/Midazolam Sedation vs. Fentanyl/Midazolam Sedation for Image-Guided Percutaneous Procedures in Interventional Radiology
CAMC Health System
SedationInterventional RadiologyBiopsy+1 more
Active, Not Recruiting·Phase 4·ketamine
Propofol-Enhanced Assessment of Ketamine for Chronic Pain and Depression
Stanford University
Chronic PainDepression
Active, Not Recruiting·Phase 1·ketamine
Integrating Ketamine Effects on Neuronal Molecular Signatures and the Brain Functional and Structural Connectome
Massachusetts General Hospital
DepressionSuicide
Active, Not Recruiting·N/A·ketamine
Link Between Reduction of Suicide Ideation by Esketamine in Add-On and Initial Levels of Psychological Pain and Anhedonia
University Hospital, Montpellier
Depression - Major Depressive DisorderDepression DisorderSuicide
Active, Not Recruiting·Phase 2·ketamine
Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment
Icahn School of Medicine at Mount Sinai
DepressionMild Cognitive Impairment
Companies & Research
Organizations developing Ketamine-based therapies